Post-surgical follow-up of primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 by Coutinho, Flavia L. et al.
  Universidade de São Paulo
 
2012
 
Post-surgical follow-up of primary
hyperparathyroidism associated with multiple
endocrine neoplasia type 1
 
 
Clinics,v.67,n.,p.169-172,2012
http://www.producao.usp.br/handle/BDPI/40468
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade Scielo
REVIEW
Post-surgical follow-up of primary
hyperparathyroidism associated with multiple
endocrine neoplasia type 1
Flavia L. Coutinho,I Delmar M. Lourenco Jr.,I Rodrigo A. Toledo,I Fabio L. M. Montenegro,II Sergio P. A.
ToledoI
I Endocrine Genetics Unit (LIM-25), Endocrinology Division, Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo. IIHead and Neck
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The bone mineral density increments in patients with sporadic primary hyperparathyroidism after parathyroidect-
omy have been studied by several investigators, but few have investigated this topic in primary hyperparathyroidism
associated with multiple endocrine neoplasia type 1. Further, as far as we know, only two studies have consistently
evaluated bone mineral density values after parathyroidectomy in cases of primary hyperparathyroidism associated
with multiple endocrine neoplasia type 1. Here we revised the impact of parathyroidectomy (particularly total
parathyroidectomy followed by autologous parathyroid implant into the forearm) on bone mineral density values
in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1. Significant
increases in bone mineral density in the lumbar spine and femoral neck values were found, although no short-term
(15 months) improvement in bone mineral density at the proximal third of the distal radius was observed.
Additionally, short-term and medium-term calcium and parathyroid hormone values after parathyroidectomy in
patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 are discussed. In
most cases, this surgical approach was able to restore normal calcium/parathyroid hormone levels and ultimately
lead to discontinuation of calcium and calcitriol supplementation.
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INTRODUCTION
Primary hyperparathyroidism (HPT) is a common endo-
crine disorder, affecting 0.3% of the general population and
1–3% of postmenopausal women (1). It is characterized by
hypercalcemia and elevated or inappropriately normal
levels of parathyroid hormone (PTH). Most patients (80–
95%) present with the sporadic form of the disease (s-HPT),
whereas familial cases may be associated with multiple
endocrine neoplasia type 1 (MEN1) and MEN type 2, jaw
tumor syndrome, neonatal severe primary HPT, and
familial isolated HPT (2–4). HPT disease associated with
MEN1 (HPT/MEN1) differs in many aspects from s-HPT,
including its clinical, pathological, and genetic character-
istics, and it is therefore treated with different surgical
protocols, and exhibits different cure rates and outcomes
(2,5,6). In contrast to s-HPT, HPT/MEN1 presents as a
multiglandular parathyroid neoplasia (hyperplasia versus
adenoma), has an earlier disease onset (20 versus 40 years
of age), has a higher recurrence rate after parathyroidect-
omy (PTX), and is often less aggressive (2,5,7). A
potentially more virulent form of HPT has also been
reported in association with Zollinger–Ellison syndrome
(8). We have found an increase in the frequency of HPT/
MEN1in recent years, since familial genetic screening for
the MEN1 gene was introduced into routine use in our
hospital (9–11).
PTX IN HPT/MEN1
Instead of adenomectomy, the procedure recommended
for s-HPT, two basic surgical procedures have been
performed for the treatment of patients with HPT/MEN1:
subtotal partial parathyroidectomy (SPTX) and total para-
thyroidectomy (TPTX). SPTX consists of the removal of at
least 3–3.5 glands, leaving a normal parathyroid remnant of
20–30 mg, whereas TPTX consists of the removal of all four
glands followed by autologous heterotopic implant of
parathyroid tissue in the muscles of the non-dominant
forearm (8,12-16). Ultimately, in the hands of skilled
surgeons, both methods have been reported to achieve
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euparathyroidism, maintaining correct PTH secretion and
calcium metabolism, and preventing clinical complications.
BONE MINERAL DENSITY IN HPT/MEN1
Very few data on bone status in patients with HPT/
MEN1 are available in the literature, which limits compar-
isons. Burgess et al. documented high rates of early and
severe bone mineral loss in the femoral neck (FN) and
lumbar spine (LS) of 29 women in a large MEN1 family
from Tasmania (17). Of note, the authors used analysis of
the bone mineral density (BMD) to evaluate bone status in
the studied cases.
Similarly, in 2008, we confirmed the same demineraliza-
tion pattern in affected cases from an extended MEN1
family harboring a founding MEN1 germline heterozygous
mutation. We also identified the proximal one-third of the
distal radius (1/3 DR) as an early and severely compro-
mised bone site in this MEN1 family (18). Patients with
MEN1-related HPT usually have severe bone and kidney
involvement despite a milder biochemical presentation
compared with their s-HPT counterparts (19).
In 2010, our preliminary findings were confirmed in a
larger series of HPT/MEN1 cases that we were able to
study. In this latter investigation, we found that urolithiasis
occurred early (,30 years) and frequently (75%) and that it
was usually associated with kidney-related co-morbidities
(50%), as well as with renal insufficiency in the older group
(.50 years) (33%). We also verified that bone mineral-
related and urolithiasis-related renal complications in HPT/
MEN1 were of early onset, frequent, extensive, severe, and
progressive (20). Notably, the trabecular bone mineral
content in the studied cases was not protected, in contrast
to the previously reported trend in s-HPT (21-25).
Furthermore, it was recently suggested that the Menin
protein, coded by the MEN1 gene, may interfere in
osteoblast differentiation (26–28), and may also have a
direct demineralizing effect on trabecular bone in animal
models (29).
The impact of PTX in s-HPT has been widely studied, and
significant short-term bone mineral recovery of the LS and
FN has been documented (22,30,31). Conversely, 1/3 DR
BMD was previously thought to have no marked recovery
one year after PTX (31), whereas long-term mineral recovery
of the LS, FN and also 1/3 DR has been documented
(22,25,30-33).
BMD AFTER PTX IN HPT/MEN1
Data on bone mineral recovery after PTX in the specific
subset of patients with HPT/MEN1 have been published in
only two papers so far (17,34).
Data from Burgess et al.
This first study addressed the LS and FN BMD before and
after PTX in five women with HPT/MEN1. In this limited
number of patients, significant recovery of BMD was seen in
the femoral neck (3.2¡2.9%) and lumbar spine (5.2¡2.5%)
after PTX (17).
Our data
We assessed the BMD changes in 16 patients with HPT/
MEN1 11 years after total PTX followed by autologous
parathyroid implant in the forearm, using dual-energy
X-ray absorptiometry (DXA, Hologic QDR-4500 S/N
45130, Waltham, MA) (34). Significant improvements in
BMD were verified in all cases 15 months after PTX at both
the LS and FN, but not at 1/3 DR. Hence, 15 months after
PTX, the LS values increased from 0.843 to 0.909 g/cm2,
with a BMD increase of +8.4¡9.84% (p= 0.001). The FN
values rose from 0.745 to 0.798 g/cm2, and BMD increased
by +6.9¡3.17% (p= 0.0001). Conversely, no significant
changes were seen in the 1/3 DR BMD values 15 months
after PTX (34).
It was noted that pre-surgical bone mineral mass was
already compromised in the 16 patients with HPT/MEN1.
Hence, there was a high prevalence of reduced BMD (Z-
score , – 2.0) for the 1/3 DR (50%), LS (43.7%), ultradistal
radius (UDR; 43.7%), FN (25%), and total femur (TF) (18.7%)
in these cases.
BMD DATA IN s-HPT and HPT/MEN1
The BMD values after PTX in our study were between
those reported by Burgess et al. (17) in HPT/MEN1 cases,
and those seen in s-HPT (32). Furthermore, in contrast to the
short-term and long-term 1/3 DR BMD recovery reported
by Rubin et al. (32) in cases with s-HPT, we could
not document significant change in 1/3 DR BMD
(-0.6¡15.73%) during follow-up of our cases (Table 1).
These data indicate a trend for potential differences in BMD
recovery after surgery in patients with HPT/MEN1
compared with patients with s-HPT.
PTH AND CALCIUM AFTER PTX IN HPT/MEN1
In this study, immediately after PTX, all cases presented
transient signals and symptoms of hypocalcemia, associated
with low serum calcium and PTH values. Therapy with oral
calcium (,2–3 g/day) and calcitriol (,1 mg/day) supple-
ments was instituted in all cases to achieve normal calcemia.
This treatment was maintained for 4–5 months (with an
average time of 8.3 months), although progressively lower
therapeutic doses were needed over this time. The post-
surgical pattern of increasing serum levels of PTH secreted
by the parathyroid implant is shown in Figure 1. A slow
biochemical (calcium, PTH) recovery after successful total
PTX followed by autologous parathyroid implantation was
verified in this series of patients. Fully viable parathyroid
Table 1 - Mean percentage change in bone mineral
density at three sites in patients with
hyperparathyroidism associated with multiple endocrine
neoplasia type 1 (HPT/MEN1) and those with sporadic
HPT, after parathyroidectomy.
Burgess (17)
(HPT/MEN1)
Coutinho (34)
(HPT/MEN1)
Rubin (32)
(s-HPT)
LS (%) 5.2 8.4 9
FN (%) 3.2 6.9 5
1/3 DR (%) NA –0.6 4
Post-surgical mean
time (months)
18 15 12
LS, lumbar spine; FN, femoral neck; 1/3 DR, distal third of radius; NA, data
not evaluated.
In all cases studied by Coutinho et al. (34) total parathyroidectomy was
followed by autologous parathyroid implant, and bone mineral density
values were assessed using dual-energy X-ray absorptiometry (Hologic
apparatus).
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implants with consistent mean PTH secretion values
(32.6¡9.1 ng/ml) were obtained 9 months after PTX (34).
Based on these data, we conclude that in patients with
HPT/MEN1, bone demineralization is an important com-
plication and should be routinely evaluated before PTX, and
patients should be followed up for several years. Calcium
and calcitriol supplementation is frequently needed for
several months after PTX until efficient function of the
autologous parathyroid implant is achieved.
In conclusion, in our experience there is a marked short-
term improvement in BMD at the LS and FN in most
patients with HPT/MEN1 after total PTX followed by
autologous parathyroid implant into the forearm, although
BMD at the 1/3 DR may take longer to recover (.18
months) after surgery. Hence, LS and FN BMDs are the
better sites to investigate BMD after PTX in patients with
HPT/MEN1.
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